Sunday, November 17, 2024
Home Blog Page 3492

Singapore’s First Legacy Planning Game Championship to Launch in November

Singapore’s First Legacy Planning Game Championship to Launch in November

SINGAPORE – Media OutReach – 3 November 2023 – Immortalize, Singapore’s most comprehensive elderhood marketplace and information provider, is pleased to announce the start of a nationwide competition for Will of Fortune by Immortalize (“WOFI”), an immersive strategy card game that aims to break down the taboo surrounding legacy planning. The competitions are organized in conjunction with supporters like Metis Global (Singapore) Pte. Limited., and Huttons Asia Pte Ltd.

WOFI was launched earlier in June this year and uses fun, engaging and repeatedly playable content to help people learn about the tools and professionals involved in planning for one’s legacy. To further encourage conversations on this critical but often neglected topic, Immortalize will be holding WOFI Championship tryouts and competitions across the island nation to spur discussions on the importance of legacy planning.

The WOFI Championship is divided into three sub-categories:

  1. General Championship – Open to Singaporeans and foreigners of all ages;
  2. Finance Professionals League – Open to all financial advisors, wealth managers, traders, investment bankers and other professionals in the finance industry; and
  3. Tertiary Education League – Open to all University, Polytechnic and other students undergoing tertiary education.

Winners of the sub-categories will proceed to compete in the WOFI Championship Grand Final where they will vie for the Legacy Grandmaster title. Over SG$10,000 worth of cash, prizes and/or gifts await winners and participants of the WOFI Championships and tryouts.

Metis Global (Singapore) Pte. Limited., a licensed trust company in Singapore, and Huttons Asia Pte Ltd, Singapore’s largest private real estate agency, are the main supporters of the WOFI Championship. Bequest Private Limited, an estate planning firm, is a supporter of the WOFI Championship – Tertiary Education League.

Interested parties can try out the WOFI game at every Immortalize Elderhood Planning Fair, starting from November 10, 2023.

To learn more about WOFI, please visit www.immortalize.io/will-of-fortune.

For more information on WOFI Championships, prizes, and to register, please visit www.immortalize.io/wofi-championships.

For details on Immortalize Elderhood Planning Fair dates and locations, please visit www.immortalize.io/elderhood-planning-fair

The following supporters of WOFI Championships are available for media interviews. Please send requests to [email protected].

WOFI CHAMPIONSHIP – KEY SUPPORTERS

About Metis Global (Singapore) Pte. Limited (“Metis SG”)
A subsidiary of the Metis Global Group and operating under the Trust Business License issued by the Monetary Authority of Singapore and audited by Ernest & Young. Dr. German Cheung (Founder of Metis Global Group) strongly believes that trusts can be simple and should not be exclusive only to the high-net-worth individuals. This motivated him to venture into the business of providing retail trust solutions since 2013. He has set a vision for the group – “A Trusted Partner in Creating Financial Legacies”.

Metis SG offers simple, accessible, and affordable trust solutions with the aim of enabling more people to have access to the benefits of trust while addressing their financial needs.

Comments from Alex NG, Deputy CEO, Metis SG
“A trust embodies an enduring expression of affection and duty to your loved ones, serving as evidence of your commitment to safeguard and provide for them in your absence. It encapsulates the fundamental essence of estate and legacy planning,” Alex said. “Regrettably, there is limited knowledge and awareness on this subject amongst the general public and I think it is a superb idea to enhance our understanding, whilst at the same time fostering openness and togetherness among friends and family members, by engaging in enjoyable and entertaining educational games like WOFI.”

About Huttons Asia Pte Ltd
Established since 2002, Huttons Group(合登集团)is Singapore’s Largest Private Real Estate Agency and has won numerous awards for innovative technologies and industry first initiatives over the years. In association with Savills, Huttons has more than 5,400 professionals marketing hundreds of local and international projects over 8 countries.

As The Preferred Agency of Choice, Huttons strives to provide the highest level of service to clients through vast knowledge across different market segments, and with empathy. Growing from strength to strength, Huttons is also expanding rapidly and extending their reach abroad, making it a seamless experience for clients to buy and sell properties globally.

Comments from Mark YIP, CEO, Huttons Asia Pte Ltd
“Huttons is proud to be the first and exclusive real estate agency to support this Legacy Planning Card Game initiative and empower the wider public to learn while planning for their own legacy in real life. As a strong advocate of real estate literacy and asset progression, we believe in the importance of associates assisting clients with their entire property portfolios in addition to planning for retirement and beyond,” according to Mark.

“Huttons also conducts regular consumer educational seminars to raise awareness about market sentiments and trends through data analytics. Internally, we will continue to invest in raising the knowledge and skills of our associates so that they can provide prompt and professional assistance at every touchpoint and go the extra mile to deliver a high level of client satisfaction for their next dream home or investment property,” Mark added.

WOFI Championship – Tertiary Education League Supporter

Bequest Private Limited
Founded in 2013, Bequest is recognized as the premier one-stop estate solutions provider in Singapore, offering a full suite of services and solutions for preparing one’s last stage of life to ensure a smooth transition for family members and loved ones.

Hashtag: #Immortalize #WOFIChampionship #WillofFortunebyImmortalize #WOFI #cardgame #Elderhood #legacyplanning #estateplanning #elderhoodplanning



The issuer is solely responsible for the content of this announcement.

About Immortalize

Immortalize is an elderhood marketplace and information provider. Immortalize educates people on what they need to know about legacy, retirement, and eldercare planning, helps them find the right solution providers, and assists them in getting these important matters sorted easily. Immortalize makes ageing easy.”

//www.instagram.com/embed.js

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.

An Irreverent Remix of the Classics: A BATHING APE® and Bored Ape Yacht Club Reveal their Collection

0

MIAMI, Nov. 3, 2023 /PRNewswire/ — Yuga Labs and A BATHING APE®  (BAPE®) today unveiled the full collection of their collaboration, announced in September.

BAPE® X BAYC linked up to take their fans back to the early 2000s when streetwear brands were more avant garde and didn’t take themselves too seriously. The collection is brought to life in an array of apparel, footwear, and accessories that are loud, irreverent, and reminiscent of the laid back opulence that both brands embody.

Key garments include a coach’s jacket mashing up their logos and names as A Bored Ape. A playful mix of each brand’s primate mascot— Curtis the Ape and BABY MILO®– are featured in tees exclusive to Bored Ape holders and BAPETAVERSE members, along with the BAPE® classic ABC camo pullover hoodie. The collection also boasts accessories like adjustable mesh trucker caps, bucket hats, and, for those lazy couch days, a BAYC Curtis rug and a BAPE® cushion.

BAPE® X BAYC also includes a remix to the classic BAPE STA™ with a clear, ice rubber outsole and ice rubber outsole showing Curtis. The 1,000 pairs of shoes produced for this limited collection are individually numbered with a second set of BAPE® X BAYC camo laces in the box.

"This collection is reminiscent of a time where collecting streetwear was about being in the know, ahead of the curve" said Michael Ghory, VP of Apparel at Yuga Labs. "It offers our communities a twist on the classic designs from BAPE®’s vault, in extremely limited quantities, so apes are guaranteed to always stay unique."

"Through immense and intense effort, BAPE® strives to present an unprecedented collaboration to both Web2 and Web3 communities where two can be easily collided nowadays, in the ever-changing fashion industry," said Thomas Hui, Chief Operations Officer at BAPE® Hong Kong Limited.

The BAPE® X BAYC collection drops exclusively for BAYC members at ApeFest and online, with token-gated access on November 4th. Following ApeFest, BAPETAVERSE members can access online, and finally, in December the collection will be released at BAPE STORE® and BAPE.COM globally.

You can preview the BAPE® X BAYC collection designs, along with a sizing chart here.

About Yuga Labs
Yuga Labs is a web3 company shaping the future through storytelling, experiences, and community. Guided by the belief that the potential of web3 can be realized when we start with imagination, not limitations, Yuga’s initiatives aim to reinvent what real-world utility for NFTs look like and push the space forward as a whole. Since their launch in April 2021 with flagship collection Bored Ape Yacht Club, they’ve made headlines as one of the first companies to release IP licenses to their NFT holders, acquired and released rights to other top collections (CryptoPunks and Meebits), and made web3 history with record-breaking synchronized player participation in their newest initiative, Otherside. One of the most ambitious interactive metaverse projects to date, Otherside is built with the community, rebelling against traditional walled gardens in gaming spaces. In March 2022, Yuga Labs raised a $450M seed round at a $4B valuation.

About BAPE®
Born in the heart of Harajuku, Japan in 1993, BAPE®️ has served as a symbol of Japanese street fashion for more than 30 years. Striving to introduce Japanese fashion culture to the world, BAPE®️ has cemented a series of iconic motifs, original patterns, and characters such as the "APE HEAD," "BAPE®️ CAMO," and "BABY MILO®," and more.

With over 40 stores globally, BAPE®️ is recognized as a symbol of street fashion, standing as one of the most coveted and exclusive brands worldwide. To cater to a growing customer base, diffusion lines like "MR. BATHING APE," "AAPE BY A BATHING APE®️," "BAPY®️," "APEE," and "BAPE BLACK®️" have been created as part of the brand’s continued growth across its expansive customer segments. Beyond apparel, BAPE®️ has embraced lifestyle landscape through art, furniture, toys, and more, allowing fans to experience the brand in different aspects of life. BAPE®️ has also pushed the boundaries of limitless ideation across different outlooks, successfully collaborating with established international brands and imprints, proving itself as an authoritative force in street fashion.

Source : An Irreverent Remix of the Classics: A BATHING APE® and Bored Ape Yacht Club Reveal their Collection

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

0

Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness. The interim Phase 2a results demonstrate a sustained >20% reduction of Intraocular Pressure after 6 months with a favorable safety profile; 8 (out of 17 subjects) successfully dosed with a second implant. The implant is the first biodegradable ocular implant in development that has the potential to be used safely for repeat dosing.

MELBOURNE, Australia, Nov. 3, 2023 /PRNewswire/ — PolyActiva is a Melbourne-based ophthalmology company developing a novel proprietary drug delivery platform. Today the company reported promising interim results from an ongoing Phase 2a clinical study for its PA5108 Ocular Implant in subjects with mild to moderate glaucoma. This ocular implant is designed to deliver 6 months of latanoprost and to biodegrade, allowing for repeat dosing. In the initial cohort, PA5108 showed a >20% reduction in intraocular pressure (IOP) at 12 weeks and 26 weeks. In a further cohort, the implant’s rapid biodegradation profile has also allowed for eight (8) patients thus far to receive a second implant at 21 weeks, providing ongoing, uninterrupted therapy, with no product related adverse effects.

"For ocular implants to ultimately replace daily eye drops for the treatment of glaucoma, they need to be suitable for repeat administration, which has been a principal goal of PolyActiva’s development program. Our Phase 2a results indicate we are well placed to meet that objective," says Vanessa Waddell, CEO of PolyActiva.

Treating glaucoma with daily eye drops has been a mainstay of glaucoma therapy, however between 41-90% of patients do not correctly administer their drops after one year. Ineffective treatment and poor adherence can accelerate loss of sight.

"Sustained drug delivery via an implant could reduce the reliance on daily eye drops and ensure that the correct amount of medicine is delivered consistently, every day," Waddell continues. "The implants received by these trial participants were present for 26 weeks before they biodegraded, which gives us confidence that our technology will be able to deliver a long-term treatment option for glaucoma patients. We look forward to continuing our development of this product as we plan for confirmatory trials in the US."

Glaucoma affects over 2.3 million patients in the US and represents a total addressable market of over US$4.5bn per annum.

PolyActiva will present its interim Phase 2a data at the Eyecelerator Ophthalmic Innovation Conference in San Francisco on November 2nd. The company plans to initiate its Phase 2b clinical trial in the US, Australia, and New Zealand in 2024.

About PolyActiva

PolyActiva is an innovative clinical-stage ophthalmology company with a unique proprietary polymeric prodrug technology that enables site-specific, precise and controlled drug delivery to the eye.

Our mission is to become a leader in ophthalmic medicine by providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life.

About PolyActiva’s Phase 2a clinical study

A Phase 2a open label dose escalation study of the Latanoprost Acid Ocular Implant in patients with mild to moderate glaucoma is being conducted in Australia and New Zealand. The primary objectives of the study are to demonstrate the minimum effective dose of implant to achieve a ≥ 20% reduction in intraocular pressure at 12 weeks and to assess the safety and tolerability of the implant. Three subject cohorts were recruited, a low dose cohort (n=10), a mid-dose cohort (n=10) and a repeat dose cohort (n=17). A high dose cohort was not recruited after the efficacy targets were achieved with the low and mid dose implants. All subjects are required to washout their IOP lowering medication prior to receiving their implant. Subjects in the repeat dose cohort receive their first low dose implant on Day 0 of the study and second within 7 days of their week 21 assessment. Patient enrolment has now been completed. Patients are monitored on study until their implant biodegrades and their IOP returns to levels requiring further medication.

Source : PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Latham & Watkins Names 34 New Partners and 48 New Counsel

0

The firm’s annual promotion of associates includes exceptional lawyers who have built vibrant practices.

NEW YORK, Nov. 3, 2023 /PRNewswire/ — Latham & Watkins LLP1 is pleased to announce that 34 associates have been elected to the partnership and another 48 associates have been promoted to the role of counsel, effective January 1, 2024.

"I am extremely proud of our new partners and counsel. Each are committed to excellence and innovation, and their legal talents and dedication to client service distinguish them as outstanding lawyers. They add tremendous expertise to our global platform and strength to our market-leading practices, and we are excited to see their continued success," said Rich Trobman, Chair and Managing Partner of Latham & Watkins.

"This is a milestone we look forward to each year, when we celebrate our new partners and counsel. All are strong team players who have built robust practices. This diverse group has consistently demonstrated the sector knowledge, commitment to teamwork, and dedication to client service that our clients expect," added Nathan Ajiashvili, Chair of the firm’s Associates Committee. A signature Latham tradition, the Associates Committee consists of nearly equal numbers of partners and associates who collaborate on key responsibilities, including recommending promotions to partner and counsel each year.

The 34 lawyers elected to the partnership are:

ASIA

Chuan Wei Kong (Singapore) is a member of the Banking Practice and Finance Department. He advises borrowers and lenders on leveraged finance, margin lending, special situations, and other banking transactions across Southeast Asia. He received his Postgraduate Diploma in Legal Practice from the College of Law in 2011.

EUROPE AND MIDDLE EAST

Abdullah Alsaeed (Riyadh) is a member of the White Collar Defense & Investigations Practice and Litigation & Trial Department. He represents clients in Saudi Arabia and globally on regulatory and commercial litigation matters. He earned his LLM from the University of Southern California in 2014 and his LLB from Al-Imam Muhammad Ibn Saud Islamic University in 2011.

Chris Armstrong (London) is a member of the Structured Finance Practice and Finance Department. He advises private equity, private capital, and bank clients on structured and bespoke financing opportunities, including preferred equity and asset-backed financings. He received a Graduate Diploma in Law from BPP Law School in 2012 and a Master of Studies from Oxford University in 2010.

Suneel Basson-Bhatoa (London) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. He represents private equity sponsors and portfolio companies on cross-border transactions and advises clients on M&A, joint ventures, and general corporate matters. He completed his LPC at the College of Law, London in 2013 and earned his LLB from City University of London in 2011.

Giuditta Caldini (Brussels) is a member of the Antitrust & Competition Practice and Litigation & Trial Department. She advises clients on complex competition law matters, including merger control, antitrust investigations, and litigation before EU courts. She received her LLM from College of Europe – Bruges in 2013 and her LLB from King’s College London in 2012.

Anthemis Economou (Brussels) is a member of the Antitrust & Competition Practice and Litigation & Trial Department. She advises clients on complex M&A and private equity transactions and antitrust investigations. She received her LLM in Competition and Corporate Law from the London School of Economics in 2014, an LLM in Commercial Law from the University of Athens in 2012, and her LLB from the University of Athens in 2010.

Gabriel Lakeman (London) is a member of the Emerging Companies & Growth Practice and Corporate Department. He advises startups, established fintechs, and financial services firms on product structuring and broader strategy within the financial regulatory landscape. He completed his LPC at the College of Law, London in 2013 and earned a PhD from University College London in 2011.

Tracy Liu (London) is a member of the Banking Practice and Finance Department. She advises financial institutions and corporate borrowers on complex cross-border finance transactions, including leveraged acquisition financings, liability management transactions, bank/bond financings, and private credit financings. She earned her Masters of Applied Finance from Kaplan in 2019 and her LLB from the University of Sydney in 2011.

Aoife McCabe (London) is a member of the Transactional Tax Practice and Tax Department. She advises financial institutions, private equity funds, and multinational corporations on complex transactional tax matters. She completed her LPC and GDL at BPP Law School in 2012 and 2011, respectively, received her LLM from the Institute for Law and Finance at Goethe University Frankfurt am Main in 2010, and obtained her BCL from University College Cork in 2009.

Hayden Teo (London) is a member of the Banking Practice and Finance Department. He advises private equity sponsors and corporate borrowers on acquisition and leveraged financings, bridge financings, refinancings, and other lending transactions. He earned his LLB from the University of Western Australia in 2010.

UNITED STATES

Megan Alessi (New York) is a member of the Executive Compensation, Employment & Benefits Practice and Tax Department. She advises public and private companies on benefits and compensation matters in connection with M&A and other corporate transactions. She received her Executive LLM from New York University School of Law in 2016 and her JD from Fordham University School of Law in 2011.

Erin Bergey (New York) is a member of the Investment Funds Practice and Corporate Department. She advises private capital sponsors across industries on fund formation, investment structuring, and other related matters, including co-investments and internal sponsor economic arrangements. She earned her JD from Duke University School of Law in 2015.

Tessa Bernhardt (Bay Area) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. She advises public companies, multinational corporations, private equity sponsors, and special committees on complex transactions, activism defense, and corporate governance. She received her JD and LLM from Duke University School of Law in 2015.

Aaron Bernstein (New York) is a member of the Transactional Tax Practice and Tax Department. He advises on US domestic and cross-border transactions, including derivatives, capital markets and financing transactions, and structured products. He earned his LLM and JD from New York University School of Law in 2016 and 2014, respectively.

Blake Davis (Bay Area) is a member of the Intellectual Property Litigation Practice and Litigation & Trial Department. He focuses on patent and trade secret litigation in US district courts and at the US International Trade Commission and the Patent Trial and Appeal Board. He received his JD from Columbia Law School in 2013 and his BS in Electrical Engineering from the University of Colorado Boulder in 2009.

Alex Harris (Boston) is a member of the Private Equity Finance Practice and Finance Department. He advises private equity sponsors and their portfolio companies on acquisition finance and debt financing transactions, with a particular focus on the middle market. He earned his JD from Cornell Law School in 2014.

Kevin Jakopchek (Chicago) is a member of the Complex Commercial Litigation Practice and Litigation & Trial Department. He represents public and private companies, private equity portfolio firms, and others in litigation involving contract disputes, fiduciary duty and fraud claims, IP matters, and class actions. He received his JD from Northwestern University Pritzker School of Law in 2014.

Alicia Jovais (Bay Area) is a member of the Antitrust & Competition Practice and Litigation & Trial Department. She represents public and private companies in all aspects of antitrust litigation and related counseling, including consumer class actions, monopolization and conspiracy claims, licensing disputes, and state unfair competition matters. She earned her JD from the University of California College of the Law, San Francisco in 2013.

Jana Kovich (Chicago) is a member of the Emerging Companies & Growth Practice and Corporate Department. She advises startups and venture capital investors on a range of transactional and operational matters across the company lifecycle, including business formation and structuring, corporate governance, equity financings, and exit strategies. She received her JD and LLM from Duke University School of Law in 2015.

Victor Ludwig (New York) is a member of the Banking Practice and Finance Department. He represents investment banks and direct lenders in acquisition finance, asset-backed lending, and cross-border transactions, advising on loan products ranging from large-cap syndicated loans to highly structured asset-based facilities. He earned his JD from Georgetown University Law Center in 2008.

Cameron Lyons (New York) is a member of the Project Development & Finance Practice and Finance Department. He advises on financing transactions across credit markets in the energy and infrastructure sector, representing financial institutions, private equity firms, strategic sponsors, and developers on project financings, acquisition financings, and other transactions. He received his JD from Georgetown University Law Center in 2015.

Nima Movahedi (Orange County) is a member of the Emerging Companies & Growth Practice and Corporate Department. He advises private and public companies, venture capital and private equity firms, and investment banks on M&A, investments, joint ventures, and other complex corporate transactions, particularly in the technology and life sciences sectors. He earned his JD from Boston University School of Law in 2014.

Brianna Oller (New York) is a member of the Banking Practice and Finance Department. She represents clients in acquisition financings, direct lending, cross-border matters, and other leveraged finance transactions. She received her JD from the University of Michigan Law School in 2013.

Sean Parish (Chicago) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. He advises public and private companies, private equity sponsors, and portfolio companies on complex corporate transactions, including M&A, leveraged buyouts, strategic investments, carveouts, and joint ventures. He earned his JD from Notre Dame Law School in 2015.

Rachel Ratcliffe Payne (Austin) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. She advises public and private companies across industries on strategic and private equity M&A, take-private transactions, SEC compliance, and corporate governance. She received her JD from the University of Texas School of Law in 2014.

Liliana Ranger (Century City) is a member of the Entertainment, Sports & Media Practice and Corporate Department. She advises entertainment and media companies, financial institutions, and investors on complex M&A transactions, strategic joint ventures, company and project-level debt and equity financings, as well as content production, licensing, and distribution arrangements. She earned her JD from Columbia Law School in 2013.

James Robinson (Bay Area) is a member of the Executive Compensation, Employment & Benefits Practice and Tax Department. He counsels public and private companies on equity incentive plans, deferred compensation plans, severance and change-in-control arrangements, and employment agreements, and advises on compensation and employee benefits in corporate transactions. He received his JD from the University of Chicago Law School in 2015.

Brett Sandford (Bay Area) is a member of the Intellectual Property Litigation Practice and Litigation & Trial Department. He advises on IP litigation, including patent infringement and trade secret disputes, in district and appellate courts and before the US International Trade Commission and the Patent Trial and Appeal Board. He earned his JD from the University of California, Berkeley in 2014 and an MBA from the University of Redlands in 2010.

Elizabeth Slawsby (Boston) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. She advises private equity funds and private companies across diverse industries on complex buy-side and sell-side transactions, including leveraged buyouts, minority investments, joint ventures, and structured preferred equity investments. She received her JD from Boston College Law School in 2015.

Michael Waldman (New York) is a member of the Banking Practice and Finance Department. He represents financial institutions in leveraged finance transactions, including acquisition financings, debt restructurings, cross-border transactions, asset-based financings, recurring revenue-based financings, and margin loan financings. He earned his JD from the University of Michigan Law School in 2013.

Harrison White (Los Angeles) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. He represents private equity firms and strategics across industries, particularly clients active in middle-market transactions, on transactional insurance matters. He received his JD from New York University School of Law in 2015.

Morgan Whitworth (Bay Area) is a member of the Securities Litigation & Professional Liability Practice and Litigation & Trial Department. He represents public companies, senior officers and directors, investment managers, and professional services firms in securities and class action litigation and regulatory investigations, with particular experience in the technology sector. He earned his JD from Duke University School of Law in 2012.

Daniel Williams (New York) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. He advises private equity sponsors and their portfolio companies as well as strategic investors in M&A, dispositions, carveouts, and asset sales transactions. He received his JD from the University of Texas School of Law in 2015.

Matthew Wynne (Chicago) is a member of the Investment Funds Practice and Corporate Department. He advises US and global private capital sponsors across investment areas and asset classes on fund formation, investment structuring, and other complex transactional matters, including GP-led secondary transactions, co-investments, and internal sponsor arrangements. He earned his JD from Fordham University School of Law in 2014.

The 48 associates promoted to counsel are:

ASIA

Flora Innes (Hong Kong) is a member of the Restructuring & Special Situations Practice and Finance Department. She advises banks, credit funds, equity sponsors, insolvency practitioners, and corporate debtors on complex restructuring transactions, insolvency proceedings, and cross-border disputes. She received her LLB from the University of Sydney in 2010.

Regina Kim (Seoul) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. She advises clients in Korea and globally on cross-border M&A, joint ventures, and private equity transactions. She earned her JD from Columbia Law School in 2012.

Michael Ning (Hong Kong) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. He counsels private equity sponsors, investors, and companies on corporate transactions and investments across Asia, including M&A, privatizations, private equity and leveraged buyouts, minority investments, joint ventures, and capital markets transactions. He received his Bachelor of Laws from the University of Sydney in 2011.

Edward Tang (Hong Kong) is a member of the Emerging Companies & Growth Practice and Corporate Department. He advises clients on a range of corporate matters, including representing private equity funds and corporations in capital market offerings and M&A. He received his JD and LLM from Duke University School of Law in 2015 and his MBA from Duke University Fuqua School of Business in 2015.

EUROPE AND MIDDLE EAST

Guido Bartolomei (Milan) is a member of the Capital Markets Practice and Corporate Department. He represents private equity firms, companies, and investment banks in public and private debt and equity offerings, corporate governance, public company representation, and public M&A transactions. He earned his JD from Padua University Law School in 2012.

Erika Brini Raimondi (Milan) is a member of the Banking Practice and Finance Department. She advises clients on acquisition finance, debt capital markets and other private capital transactions, private equity finance, and restructuring transactions, as well as corporate finance. She earned her Law Degree from the University of Bologna and her LLM from King’s College London in 2013.

Carmen Esteban (Madrid) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. She advises clients in Spain and globally across industries on M&A, private equity, and general corporate matters. She received her Dual Degree in Law and Business Administration from Universidad Pontificia de Comillas in 2011 and her LLM from the Instituto de Empresa in 2013.

Amanda Fortuna (London) is a member of the Banking Practice and Finance Department. She advises a diverse range of infrastructure funds, institutional investors and lenders, sovereign wealth funds, insurance companies, and pension funds on all aspects of core and hybrid infrastructure, including on complex capital structures, financings, and acquisitions. She received her JD from the University of Toronto in 2011.

Delyth Hughes (London) is a member of the Derivatives, Equities and Structured Products Practice and Corporate Department. She advises buy- and sell-side clients on cross-border OTC derivative transactions and associated regulatory matters across a range of asset classes. She earned her Postgraduate Diploma in Legal Practice from the College of Law in 2011 and her BA (Jurisprudence) from the University of Oxford in 2009.

Giorgio Ignazzi (Milan) is a member of the Capital Markets Practice and Corporate Department. He represents private equity sponsors, issuers, private credit funds, and investment banks in debt and equity offerings, acquisition financings, and liability management transactions. He received his LLM from the University of Chicago Law School in 2014 and his JD from Roma Tre Law School in 2010.

Camilla Kehler-Weiss (Frankfurt) is a member of the Capital Markets Practice and Corporate Department. She represents both issuers and investment banks in IPOs and other equity capital markets transactions and in general corporate law matters. She completed the Second German State Exam at the Higher Regional Court, Frankfurt in 2008, received her Dr. iur. from the University of Mannheim in 2007, and completed the First German State Exam at Heidelberg University in 2004.

Anne Mainwaring (London) is a member of the Financial Regulatory Practice and Corporate Department. She advises clients on UK and EU regulatory developments relevant to environmental, social, and governance (ESG) matters, including in relation to compliance with ongoing ESG regulatory developments across multiple regulatory regimes. She completed her LPC from the College of Law in 2009 and received her LLB from the University of Exeter in 2008.

Veronika Miskovichova (Madrid) is a member of the Real Estate Practice and Corporate Department. She advises clients on M&A and private equity transactions with a real estate component, joint ventures, financing and refinancing real estate assets, and structured finance. She earned her Degree in Law from the Universidad de Granada in 2010.

Hayley Pizzey (London) is a member of the Complex Commercial Litigation Practice and Litigation & Trial Department. She advises clients in a range of multijurisdictional litigation and regulatory matters, particularly commercial litigation, contentious data privacy, cybersecurity, and antitrust matters, and regulatory investigations. She completed her LPC from the College of Law, Guildford in 2008 and obtained her LLB from the University of Surrey in 2006.

Alain Traill (London) is a member of the Data & Technology Transactions Practice and Corporate Department. He advises clients across sectors on outsourcing projects, platform and technology solutions, and complex commercial contracts and renegotiations. He earned his Diploma in Legal Practice from Glasgow Graduate School of Law in 2010 and his LLB from the University of Glasgow in 2009.

Blanca Vázquez de Castro (Madrid) is a member of the Transactional Tax Practice and Tax Department. She advises companies in Spain and global private equity firms on strategic tax matters in M&A, finance, and restructuring deals, with particular experience in the real estate, telecommunications, and financial services industries. She received her BA in Law & Business Administration from Universidad Autónoma de Madrid in 2011.

UNITED STATES

Francis Acott (Bay Area) is a member of the Complex Commercial Litigation Practice and Litigation & Trial Department. He represents clients across multiple industries in class actions and complex civil litigation. He received his JD from Northwestern University Pritzker School of Law in 2014.

Julian Azran (New York) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. He represents public and private companies and private equity funds in M&A, joint ventures, leveraged buyouts, and public and private investments, with a focus on entertainment, sports, and media transactions. He earned his JD from Columbia Law School in 2015.

Lauren Bewley (New York) is a member of the Transactional Tax Practice and Tax Department. She advises private fund sponsors on fund formation and operation and represents clients in capital markets and financing transactions, restructurings, and joint ventures. She earned her LLM from New York University School of Law in 2014 and her JD from Emory University School of Law in 2013.

James Blackburn (Washington, D.C.) is a member of the Project Development & Finance Practice and Finance Department. He represents clients in the energy sector in proceedings before federal and state regulators and in district, federal, and appellate courts concerning merger, rate, enforcement, markets, and policy issues. He received his JD from The George Washington University in 2013.

Corey Calabrese (New York) is a member of the Securities Litigation & Professional Liability Practice and Litigation & Trial Department. She represents financial institutions and public companies and their senior officers and directors in securities class actions, corporate governance litigation, SEC and other regulatory investigations, antitrust matters, and complex commercial litigation. She earned her JD from Fordham University School of Law in 2010.

Hannah Cary (San Diego) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. She counsels clients on all forms of transactional insurance, including representations and warranties, tax, and contingent-risk policies, both in the context of transactions and with respect to claims. She received her JD from the University of Southern California Gould School of Law in 2014.

Joshua Chao (San Diego) is a member of the Banking Practice and Finance Department. He represents corporate borrowers, investment banks, direct lenders, and other financial institutions in corporate finance transactions across industries, focusing on leveraged finance in the context of acquisitions, refinancings, and recapitalizations. He earned his JD from Northwestern University Pritzker School of Law in 2012.

Jordan Cook (Orange County) is a member of the Securities Litigation & Professional Liability Practice and Litigation & Trial Department. She represents clients in complex commercial litigation, with a focus on securities litigation, shareholder derivative litigation, complex business disputes, professional liability, and class actions. She received her JD from the University of Southern California Gould School of Law in 2013.

Donald Cooley (Washington, D.C.) is a member of the Private Equity Finance Practice and Finance Department. He represents borrowers in secured and unsecured lending and other financing transactions, including private equity and private debt subscription lines of credit, ESG-linked credit facilities, acquisition and carveout financings, and debt restructurings. He earned his JD from New York University School of Law in 2015.

Zachary Eddington (Washington, D.C.) is a member of the White Collar Defense & Investigations Practice and Litigation & Trial Department. He advises clients in matters before the Committee on Foreign Investment in the United States (CFIUS) and advises clients on CFIUS issues. He received his JD from Harvard Law School in 2014.

Benjamin Gelfand (Houston) is a member of the Banking Practice and Finance Department. He represents public and private borrowers, private equity sponsors, and direct and institutional lenders in complex financing transactions, with an emphasis on the technology, life sciences, and energy industries. He earned his JD from Georgetown University Law Center in 2015.

Joanna Gorska (San Diego) is a member of the Project Development & Finance Practice and Finance Department. She advises sponsors, commercial banks, and other financial institutions on developing and financing projects across multiple sectors, with a focus on renewable energy projects. She completed her LPC at BPP Law School in 2012 and received her MPhil and DPhil from Oxford University.

Allison Harms (Bay Area) is a member of the Intellectual Property Litigation Practice and Litigation & Trial Department. She represents technology and life sciences clients in patent and other IP disputes before federal district and appellate courts, the US International Trade Commission, and the Patent Trial and Appeal Board. She earned her JD from the University of California College of the Law, San Francisco in 2014.

Tiffany Ikeda (Century City) is a member of the Complex Commercial Litigation Practice and Litigation & Trial Department. She represents businesses in a range of complex commercial litigation matters in state and federal courts, with a focus on IP, insolvency, and entertainment and media litigation. She received her JD from Columbia Law School in 2011.

David Kowalski (San Diego) is a member of the Complex Commercial Litigation Practice and Litigation & Trial Department. He represents clients through trial in complex litigation matters in federal and state courts, including unfair competition, fraud, contract, and patent and other IP disputes. He earned his JD from the University of Michigan Law School in 2009.

Shannon Lankenau (Bay Area) is a member of the Environment, Land & Resources Practice and Litigation & Trial Department. She represents clients in complex environmental disputes, including litigation involving claims of public nuisance, trespass, products liability, and natural resources damages. She received her JD from the University of California College of the Law, San Francisco in 2013.

Morgan Maddoux (Washington, D.C.) is a member of the White Collar Defense & Investigations Practice and Litigation & Trial Department. She represents government contractors in investigations and litigation involving the False Claims Act and other allegations of fraudulent conduct, bid protests, and government contract compliance matters. She earned her JD from the University of New Mexico School of Law in 2014.

Max Mazzelli (Bay Area) is a member of the Connectivity, Privacy & Information Practice and Litigation & Trial Department. He counsels clients in the US and globally across multiple sectors on cybersecurity, data privacy, and consumer protection issues, advising on regulatory compliance and investigations, litigation, and product counseling. He received his JD from the University of California College of the Law, San Francisco in 2014.

Elizabeth Morris (New York) is a member of the Complex Commercial Litigation Practice and Litigation & Trial Department. She represents debtors and creditors in a range of bankruptcy-related matters as well as plaintiffs and defendants in complex commercial litigation. She earned her JD from Fordham University School of Law in 2013.

Juan Carlos Olivares (Los Angeles) is a member of the Banking Practice and Finance Department. He represents direct lenders, business development companies and other financial institutions, and equity sponsors and other borrowers in structuring, negotiating, and documenting various financial transactions. He received his JD from the University of Southern California Gould School of Law in 2014.

Karen Ritter (New York) is a member of the Real Estate Practice and Corporate Department. She advises clients on various real estate transactions, including commercial dispositions and acquisitions, leasing, M&A and private equity transactions, and development projects. She earned her JD from the University of Virginia School of Law in 2015.

Nathan Saper (Los Angeles) is a member of the White Collar Defense & Investigations Practice and Litigation & Trial Department. He represents clients in complex civil disputes, investigations, and enforcement actions before government agencies and courts throughout the US, and conducts internal investigations across a range of industries and geographies. He received his JD from Northwestern University Pritzker School of Law in 2013.

Sara Schlau (Orange County) is a member of the Executive Compensation, Employment & Benefits Practice and Tax Department. She advises public and private companies and private equity funds on the employee benefits and compensation aspects of corporate transactions including M&A, corporate financings, and IPOs. She earned her JD from Stanford Law School in 2014.

Adam Shamah (New York) is a member of the Complex Commercial Litigation Practice and Litigation & Trial Department. He represents technology companies, financial institutions, and multinational public corporations in complex commercial disputes, class actions, M&A litigation, and securities litigation. He received his JD from New York University School of Law in 2014.

Katherine Stork (Chicago) is a member of the Banking Practice and Finance Department. She represents financial institutions, corporate borrowers, and private equity sponsors in a variety of financing matters, including secured and unsecured credit facilities, acquisition financings, and recapitalizations. She earned her JD from New York University School of Law in 2014.

Grant Strother (Bay Area) is a member of the Complex Commercial Litigation Practice and Litigation & Trial Department. He represents clients in complex business litigation, licensing disputes, and insurance recovery matters. He received his JD from Harvard Law School in 2012.

Polina Tulupova (New York) is a member of the Capital Markets Practice and Corporate Department. She advises clients on a full spectrum of equity derivatives and equity-linked transactions, including convertible notes, structured share-repurchase transactions, hedging and monetization transactions, margin loans, and other equity-based financing transactions. She earned her LLM from Harvard Law School in 2010.

Laura Waller (Chicago) is a member of the Executive Compensation, Employment & Benefits Practice and Tax Department. She advises clients on employment-related matters in corporate transactions and counsels employers on day-to-day legal issues, including hiring practices, personnel issues, employee separations, and restrictive covenants. She received her JD from the University of Illinois College of Law in 2004.

Ryan Walsh (Orange County) is a member of the Securities Litigation & Professional Liability Practice and Litigation & Trial Department. He represents public and private companies, as well as their officers, directors, and special committees, in a variety of litigation, white collar, and enforcement matters. He earned his JD from the University of Southern California Gould School of Law in 2013.

Jennifer Wong (New York) is a member of the Mergers & Acquisitions and Private Equity Practice and Corporate Department. She represents public and private companies in transactions including domestic and cross-border buyouts, M&A, divestitures, asset acquisitions, tender offers, joint ventures, and carveouts, as well as general corporate governance matters. She received her JD from the University of Toronto Faculty of Law in 2013.

Evan Youngstrom (San Diego) is a member of the Emerging Companies & Growth Practice and Corporate Department. He advises founders, private and public companies, and venture capital and private equity firms in the technology, life sciences, and other growth industries. He earned his JD from the University of San Diego School of Law in 2015.

Christopher Yu (New York) is a member of the Capital Markets Practice and Corporate Department. He advises financial institutions, public companies, and buy-side firms on equity derivatives and equity-linked products, structured share-repurchase transactions, hedging and monetization transactions, and margin loans and other equity-based financing transactions. He received his JD from Columbia Law School in 2014.

About Latham & Watkins (lw.com)

Latham & Watkins delivers innovative solutions to complex legal and business challenges around the world. From a global platform, our lawyers advise clients on market-shaping transactions, high-stakes litigation and trials, and sophisticated regulatory matters. Latham is one of the world’s largest providers of pro bono services, steadfastly supports initiatives designed to advance diversity within the firm and the legal profession, and is committed to exploring and promoting environmental sustainability.

Notes to Editors

Latham & Watkins operates worldwide as a limited liability partnership organized under the laws of the State of Delaware (USA) with affiliated limited liability partnerships conducting the practice in France, Hong Kong, Italy, Singapore, and the United Kingdom and as an affiliated partnership conducting the practice in Japan. Latham & Watkins operates in Israel through a limited liability company, in South Korea as a Foreign Legal Consultant Office, and in Saudi Arabia through a limited liability company.

 

Source : Latham & Watkins Names 34 New Partners and 48 New Counsel

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

0

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding in the Simultaneous Presence of PD-1 & VEGF

Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumor Microenvironment with Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of VEGF in vitro

HONG KONG, Nov. 2, 2023 /PRNewswire/ — Akeso (9926.HK) today announced that its collaboration and licensing partner, Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit") will present data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab (AK112/SMT112), at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego, CA. The poster with updated data describing ivonescimab’s mechanism of action will be displayed on Saturday November 4, 2023, from 11:55am to 1:25pm Pacific Time. This mechanism of action of ivonescimab was also presented at the 2023 AACR-NCI-EORTC (American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer) Conference on Molecular Targets and Cancer Therapeutics.

Ivonescimab is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. The poster describes how ivonescimab displays unique cooperative binding to each of its intended targets with higher affinity when in the presence of both PD-1 and VEGF.

This could differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Ivonescimab’s tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the tumor microenvironment with over 18 fold increased binding affinity to PD-1 in the presence of VEGF in vitro, and over 4 times increased binding affinity to VEGF in the presence of PD-1 in vitro.  This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design is to improve upon previously established efficacy thresholds, in addition to side effects and safety profiles associated with these targets.

The marketing application for one indication of ivonescimab was accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) with priority review. Currently, there are four registrational phase III clinical trials being conducted globally, which include three head-to-head trials with PD-1 monoclonal antibody as the positive control drug, and two international multicenter clinical trials.

Summit has begun its clinical development of ivonescimab in order to establish its efficacy and safety in two proposed NSCLC indications:

Ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) (HARMONi trial) Ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3 trial)

Earlier this year, the first patient was treated in Summit’s license territories in the Phase III HARMONi clinical trial. Summit has opened clinical trial sites in the HARMONi-3 trial and expects to begin dosing patients in the current fiscal quarter.

About Ivonescimab (PD-1/VEGF bispecific antibody)
Ivonescimab is a potential first-in-class investigational PD-1/VEGF bi-specific antibody discovered by Akeso. It combines the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab is currently engaged in multiple Phase III clinical trials worldwide.

In December 2022, Akeso entered into a collaboration and license agreement for up to US$5 billion with Summit Therapeutics ("Summit"). Akeso out-licensed to Summit exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization in the United States, Canada, Europe, and Japan. Akeso will retain development and commercialization rights for the rest of the world including China. Ivonescimab is known as AK112 for Akeso’ R&D code at China and Australia, and as SMT112 for Summit’s license territories.

About Akeso, Inc.
Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address significant medical needs globally. Since our inception , we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode.

Akeso is actively developing a diverse pipeline of over 30 innovative assets in areas such as cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, NDAs for 4 drugs and 6 indications accepted, and 13 ongoing Phase III studies. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug to the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.

In June 2022, cadonilimab was approved by the NMPA and became the first commercialized bispecific IO drug globally. Another Akeso internally discovered and developed oncology product, penpulimab (a PD-1 antibody), was granted marketing approval in China in August 2021. Akeso entered into a collaboration and license agreement for up to US$5 billion with Summit Therapeutics to accelerate global development and commercialization of ivonescimab. In August, the NDA submission of ivonescimab was accepted by China’s NMPA with priority review. Akeso is listed on the Main Board of the Stock Exchange of Hong Kong Limited.

Contact Akeso Public Relations:
[email protected]

Contact Akeso Business Development:
[email protected]

Source : Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Talus Renewables Announces $22 Million Raised in Series A Financing

0

First-to-Market Commercial Modular Green Ammonia System Attracts Leading Early-Stage Agriculture, Energy & Tech Investors

NEW YORK, Nov. 2, 2023 /PRNewswire/ — Talus Renewables ("Talus"), a renewable energy infrastructure company and creator of the first modular green ammonia system deployed commercially, announced its $22 million Series A financing co-led by Material Impact and Xora Innovation, a deep tech early-stage investment platform of Temasek; joined by Cavallo Ventures, the VC arm of Wilbur-Ellis, and Rice Investment Group.

With this funding, Talus will ramp up production of its green ammonia technology, using water, air, and renewable power to revolutionize production of fertilizer, and enable on-site operations that significantly reduce the carbon footprint of historically difficult-to-decarbonize industries.

Talus’s systems’ ability to generate lower-cost, carbon-free ammonia at or near the point of use reduces or eliminates supply chain length for agriculture, mining, and industrials, with additional applications in maritime shipping, renewable energy storage, and power generation.

Talus will deliver multiple talusOne (up to 1.4 tonnes of green ammonia daily) and talusTen (up to 20 tonnes) systems beginning later this year in US and European markets. The first talusOne was installed in partnership with the Kenya Nut Company in the Kenya Highlands.

"We are gratified by our investors’ confidence in our ability to provide a more sustainable, cost-effective, and secure path forward for critical industries," said Hiro Iwanaga, Co-Founder and CEO of Talus Renewables. "The promise of rapidly deployable, modular, autonomous green ammonia systems will extend far beyond agriculture to industrial and renewable energy applications."

"Through the long-term vision that Talus has for a prosperous global economy backed by renewables, their first vertical application of creating green ammonia in situ will make a great impact in increasing the food supply chain sustainably and cost effectively," said Adam Sharkawy, Founding Partner of Material Impact. "Material Impact, which focuses on high tech scientific and engineering advances to solve large global problems, is excited to invest in Talus and support its capacity to be a clean energy game-changer."

"Xora Innovation specializes in supporting ventures tackling some of the world’s greatest challenges through the commercialization of disruptive technologies and Talus Renewables embodies this investment thesis," said Phil Inagaki, Managing Director of Xora Innovation. "One of the distinguishing features of Talus is their speed of execution. While most companies in the green ammonia space are still in the product development or project planning phase, Talus has already begun delivering systems to customers and is poised for rapid growth."

"We’re excited that Talus is helping transform our industry into a cleaner, more sustainable enterprise," said Brett Morris, Managing Director at Cavallo Ventures. "Talus’s systems have the potential to remove an element of unpredictability by enabling local production of fertilizer, lowering costs for farmers while reducing their carbon footprint."

About Talus Renewables:

Talus Renewables pioneered the first commercial, modular, zero-carbon green ammonia system that makes the production and distribution of a critical raw material cheaper, cleaner, and more reliable. Talus locally produces lower-cost, carbon-free ammonia at or near the point of use, creating value for multiple industries. The talusOne and talusTen operate on intermittent renewable power and are fully containerized and modular, enabling rapid deployments and scaling. TalusAg, a subsidiary of Talus Renewables, focuses on green ammonia production for the agriculture sector. https://www.talusag.com/.

Contact: Liz Benjamin, [email protected], 518-424-0356

Source : Talus Renewables Announces $22 Million Raised in Series A Financing

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

0

FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio I-Mab has full development and commercialization rights of felzartamab in Greater China for all indications, with Phase 3 multiple myeloma data expected in 2024, followed by a planned BLA submission

ROCKVILLE, Md. and SHANGHAI, Nov. 2, 2023 /PRNewswire/ — I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, and HI-Bio, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for felzartamab, an investigational CD38 antibody, for the treatment of primary membranous nephropathy (PMN).

"The FDA’s decision to grant felzartamab Breakthrough Therapy designation is recognition of the promising data we have collected to date, as well as an acknowledgement of the need for major advances over available therapies in the treatment of patients with PMN," said Dr. Uptal Patel, Chief Medical Officer of HI-Bio. "We believe that the cellular depletion strategy with felzartamab in PMN is applicable to many more immune-mediated diseases driven by antibodies produced in CD38+ plasma cells. For that reason, we are currently developing felzartamab in multiple diseases including PMN, IgA nephropathy, antibody-mediated rejection and lupus nephritis."

The FDA selectively grants Breakthrough Therapy Designation to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition, and preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).

The designation for felzartamab was based on clinical data submitted to the FDA, including results from M-PLACE, a Phase 1b/2a proof-of-concept, open-label study. The final analysis of the M-PLACE study has been accepted as an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting (Abstract TH-OR27), taking place November 1–5, 2023, by Brad Rovin, M.D., Director of the Division of Nephrology at Ohio State University.

I-Mab has the full rights to develop and commercialize felzartamab for all indications in Greater China which encompasses Mainland China, Hong Kong, Macau, and Taiwan. I-Mab is evaluating felzartamab in oncology and autoimmune diseases.  I-Mab is currently conducting a Phase 3 registrational study of felzartamab in combination with lenalidomide and dexamethasone as a second-line treatment for multiple myeloma (MM) in China with progression-free survival (PFS) as the primary endpoint, with a projected read-out in 2024, followed by a planned BLA submission.

"We are excited about the potential therapeutic benefit of felzartamab through this Breakthrough Therapy Designation by the FDA, following the Orphan Drug Designation received in May," said Dr. Andrew Zhu, President of I-Mab. "This designation represents an important milestone for I-Mab, our partner HI-Bio, and the PMN community as we continue to evaluate felzartamab as an innovative immunotherapy for multiple indications, including cancers and autoimmune diseases."

About Primary Membranous Nephropathy (PMN)

PMN is a rare autoantibody-mediated autoimmune kidney disease and a leading cause of nephrotic syndrome (NS) in adults worldwide. Disease onset and diagnosis typically occurs between 40 and 50 years of age, with 80% of patients presenting with nephrotic syndrome (i.e., edema, >3.5 g/day proteinuria, hypoalbuminemia). PMN is characterized by a thickening of the glomerular basement membrane (GBM) due to the formation and deposition of immune complexes in this space between podocytes and the glomerular endothelium of the kidney. 

Approximately 80% of PMN cases arise due to autoantibodies that recognize the phospholipase A2 receptor (PLA2R) antigen expressed on podocytes. Anti-PLA2R is both a diagnostic and prognostic biomarker, and total aPLA2R antibody level has been shown to be a biomarker for prognosis of outcome in patients with PMN. Other autoantibodies have been identified in patients with PMN including anti-THSD7A, NELL-1 and Sema3B, further supporting the role of antibody-secreting plasma cells in the pathophysiology of PMN. CD38+ long-lived plasma cells and plasmablasts are a main source of autoantibodies. 

There are no approved therapies for PMN. The current standard of care comprises off-label use of supportive care measures (e.g., angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, statins, and diuretics), conventional immunosuppressive treatments (ISTs) (e.g. cyclophosphamide combined with steroids and calcineurin inhibitors) or B-cell depleting agents (e.g. anti-CD20 antibodies). However, these treatments are not effective in all patients, with a significant proportion of patients not achieving remission or relapsing. In addition, conventional immunosuppressive treatments are associated with a high risk of toxicity.

About Felzartamab

Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a protein expressed on mature plasma cells. The antibody is directed against CD38 on the surface of multiple myeloma cells, which has been characterized as one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells. According to its suggested mode of action, the antibody recruits cells of the body’s immune system to kill the tumor through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The antibody does not involve complement dependent cytotoxicity, or CDC, an additional immune mechanism involved in tumor cell killing. Scientific research suggests that an anti-CD38 antibody may have therapeutic potential also in other cancers as well as autoimmune diseases. Based on a licensing agreement between MorphoSys and I-Mab signed in November 2017, I-Mab owns the exclusive rights for development and commercialization of felzartamab for all indications in Greater China, which encompasses Mainland China, Hong Kong, Macao, and Taiwan. HI-Bio in-licensed felzartamab from MorphoSys in June 2022, and holds exclusive worldwide rights for felzartamab with the exception of Greater China.

About I-Mab

I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics. I-Mab’s innovative pipeline is driven by internal R&D’s Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedInTwitter, and WeChat.

I-Mab Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from clinical studies of felzartamab, the potential implications of clinical data for patients, and I-Mab’s advancement of, and anticipated clinical development, regulatory milestones, and commercialization of felzartmab. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to I-Mab’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab’s drug candidates; I-Mab’s ability to achieve commercial success for its drug candidates, if approved; I-Mab’s ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab’s reliance on third parties to conduct drug development, manufacturing and other services; I-Mab’s limited operating history and I-Mab’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Company’s clinical development, commercial and other operations, as well as those risks more fully discussed in the "Risk Factors" section in I-Mab’s most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in I-Mab’s subsequent filings with the US Securities and Exchange Commission. All forward-looking statements are based on information currently available to I-Mab, and I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

I-Mab Contacts

Investors

Media

Tyler Ehler

Gigi Feng

Senior Director, Investor Relations

Chief Communications Officer

[email protected]

[email protected]

 

Source : Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SunCar Technology Group Inc. Releases Version 7.9.0 of its Insurance System

0

Update to Include Customers of 18 Leading NEV Companies

NEW YORK, Nov. 2, 2023 /PRNewswire/ — SunCar Technology Group Inc. ("SunCar", "we", or the "Company") (Nasdaq: SDA), a leading provider of digitalized enterprise automotive after-sales services and online auto insurance intermediation services in China, announced the release of its latest version of its cutting-edge digital insurance system, Version 7.9.0. This significant update reflects the Company’s commitment to staying at the forefront of the evolving auto insurance industry. Version 7.9.0 is currently being deployed by 18 leading new energy vehicle (NEV) companies, including Geely Auto, BYD, Nio, Xiaopeng, Nio, Li Auto, and Seres.

Over the course of the year, SunCar’s platform has undertaken comprehensive updates, driven by the dynamic shifts in our industry, the meticulous research we have conducted on user scenarios and requirements, and important collaborations with world-renowned NEV manufacturers on software development. A primary enhancement in this release is the enhanced capability for automatic storage and astute management of user insurance image data. Our system can now classify insurance image data by leveraging advanced image recognition technology, facilitating automatic storage and intelligent matching in real-world application scenarios. This enhancement underscores SunCar’s dedication to elevating the user experience of digital insurance intermediation.

Furthermore, SunCar has improved the traceability feature within the insurance intermediation process. Comprehensive image storage and management are now available throughout the entire user online operation process, regardless of the platform – mobile or PC. This innovation aligns with the market’s growing demand for a robust traceability for online insurance intermediation process.

Mr. YE Zaichang, Chairman and CEO of SunCar, commented, "I am proud of our team’s relentless efforts in bringing forth the 7.9.0 version of our insurance system. This update is a testament to SunCar’s unwavering commitment to innovation and understanding of the intricate needs of our users. By incorporating advanced technologies and responding proactively to industry dynamics, we strive to redefine excellence in the insurance technology domain. We believe this release will significantly enhance user experience, allowing us to continue setting the industry benchmark. At SunCar, our mission has always been to stay ahead, and with this update, we are taking another significant step forward, providing state-of-the-art solutions that resonate with our customers’ needs."

About SunCar Technology Group Inc.

Originally founded in 2007, SunCar is transforming the customer journey for car insurance and aftermarket services in China, the largest passenger vehicle market in the world. SunCar develops and operates online platforms that seamlessly connect drivers with a wide range of automotive services and insurance coverage options through a nationwide network of provider partners. As a result, SunCar has established itself as the leader in China in the B2B automotive after-sales services market and the online insurance market for electric vehicles. The company’s multi-tenant, cloud-based platform empowers its enterprise clients to optimally access and manage their customer database and offerings, and drivers gain access to hundreds of services from tens of thousands of independent providers in a single application. For more information, please visit: https://suncartech.com.

Forward-Looking Statements

This press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company encourages you to review other factors that may affect its future results in the Company’s annual reports and in its other filings with the Securities and Exchange Commission.

Contact Information :

SunCar:
Investor Relations: Ms. Hui Jiang
Email: [email protected]
Legal: Ms. Li Chen
Email: [email protected]

U.S. Investor Relations
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: [email protected]

 

Source : SunCar Technology Group Inc. Releases Version 7.9.0 of its Insurance System

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network